

Ependion - Weak top-line but resilient margins

Redeye remains confident on the case despite some near-term uncertainty as the market climate continues to be muted. Q3 sales fell short of our expectations while margins stayed firm. Ependion has managed to keep costs well contained while also focusing on strategic forward-looking investments in product development and geographic reach.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Ependion - Weak top-line but resilient margins